跳至主要内容
临床试验/ITMCTR2026001725
ITMCTR2026001725进行中(未招募)Unknown

Clinical Study on Modified Chaihu Guizhi Ganjiang Decoction Combined with Targeted-Immunotherapy for Primary Hepatocellular Carcinoma

Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 2026年8月1日最近更新:
适应症
干预措施

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • •(1) HCC confirmed by imaging or pathology;(2)TCM syndrome differentiation meets the diagnostic criteria for Gallbladder Heat and Spleen Cold syndrome;(3) Aged 18–75 years, regardless of gender;(4)Expected survival > 3 months, and Karnofsky Performance Status (KPS) score = 60;(5) Willing to participate in this study, with detailed and complete medical history records.

排除标准

  • •(1) with other primary malignant tumors; (2) with severe primary diseases of the cardiovascular, pulmonary, renal, or hematopoietic systems; (3) with autoimmune diseases or on long-term immunosuppressive medications that may affect the outcome measures; (4) who are pregnant or breastfeeding; (5) with poor compliance, poor tolerance, allergic diathesis, a history of mental illness, or intellectual disability

研究组 & 干预措施

Standard treatment group:Targeted-immunotherapy ;Add-on treatment group:Traditional Chinese medicine loading combined with standard treatment;

干预措施: Standard treatment group:Targeted-immunotherapy ;Add-on treatment group:Traditional Chinese medicine loading combined with standard treatment;

研究者

发起方
Hospital of Chengdu University of Traditional Chinese Medicine

相似试验